A conceptual framework for clinical trials in SLE and other multisystem diseases
Identifieur interne : 002704 ( Main/Exploration ); précédent : 002703; suivant : 002705A conceptual framework for clinical trials in SLE and other multisystem diseases
Auteurs : Matthew H. Liang ; Michael Corzillius ; Sang-Cheol Bae ; Paul Fortin ; John M. Esdaile ; Michal Abrahamowicz [Canada]Source :
- Lupus [ 0961-2033 ] ; 1999-10.
English descriptors
- Teeft :
- Active control equivalence studies, Active disease, Activity measure, Adequate power, Adverse effects, Alternative hypothesis, Arch neurol, Ares, Arthritis, Arthritis rheum, Arthritis society, Autoimmune diseases, Autoimmune disorders, Baillieres clin rheumatol, Chronic pain, Clin, Clin epidemiol, Clinical manifestations, Clinical trial, Clinical trials, Combination therapy, Conceptual framework, Congestive heart failure, Control clin trials, Cutaneous manifestations, Disease activity, Dos, Effectiveness trials, Eligibility criteria, Eligible patients, Endpoint, Entry criteria, Equivalence, Equivalence hypothesis, Equivalence trial, Equivalence trials, Erythematosus, Exclusion criteria, Experimental treatment, Fatigue severity scale, Generic measures, Health status, Homogeneous population, Impairment, Important difference, Individual patients, Induction trials, Liang, Lupus, Lupus erythematosus, Lupus manifestations, Lupus nephritis, Maintenance trials, Major change, Manifestation, Meaningful change, More drugs, Multiple organ systems, Multiple sclerosis, Null hypothesis, Organ damage, Organ involvement, Organ system, Other diseases, Other hand, Outcome measures, Parallel approach, Partial remission, Physiologic health, Placebo, Primary endpoint, Proportional hazards model, Rand corporation, Randomized, Relapse, Remission, Renal disease, Respiratory hazards, Response criteria, Response criterion, Rheumatoid arthritis, Sample size, Sample size calculations, Sample size estimates, Sample size formulae, Santa monica, Severe disease, Simulation study, Single organ, Standard therapy, Standard treatment, Statist assoc, Statistical power, Steroid, Study agent, Study question, Such cases, Such changes, Systemic, Systemic lupus erythematosus, Treatment effect, True difference, Vascular disease.
Url:
DOI: 10.1191/096120399680411290
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000891
- to stream Istex, to step Curation: 000891
- to stream Istex, to step Checkpoint: 001520
- to stream Main, to step Merge: 002740
- to stream Main, to step Curation: 002704
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A conceptual framework for clinical trials in SLE and other multisystem diseases</title><author wicri:is="90%"><name sortKey="Liang, Matthew H" sort="Liang, Matthew H" uniqKey="Liang M" first="Matthew H" last="Liang">Matthew H. Liang</name></author><author wicri:is="90%"><name sortKey="Corzillius, Michael" sort="Corzillius, Michael" uniqKey="Corzillius M" first="Michael" last="Corzillius">Michael Corzillius</name></author><author wicri:is="90%"><name sortKey="Bae, Sang Cheol" sort="Bae, Sang Cheol" uniqKey="Bae S" first="Sang-Cheol" last="Bae">Sang-Cheol Bae</name></author><author wicri:is="90%"><name sortKey="Fortin, Paul" sort="Fortin, Paul" uniqKey="Fortin P" first="Paul" last="Fortin">Paul Fortin</name></author><author wicri:is="90%"><name sortKey="Esdaile, John M" sort="Esdaile, John M" uniqKey="Esdaile J" first="John M" last="Esdaile">John M. Esdaile</name></author><author wicri:is="90%"><name sortKey="Abrahamowicz, Michal" sort="Abrahamowicz, Michal" uniqKey="Abrahamowicz M" first="Michal" last="Abrahamowicz">Michal Abrahamowicz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7EDCF533E797A0FD0E6AA6FD1F6434EC7974C335</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1191/096120399680411290</idno><idno type="url">https://api.istex.fr/ark:/67375/M70-3QCHP956-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000891</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000891</idno><idno type="wicri:Area/Istex/Curation">000891</idno><idno type="wicri:Area/Istex/Checkpoint">001520</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001520</idno><idno type="wicri:doubleKey">0961-2033:1999:Liang M:a:conceptual:framework</idno><idno type="wicri:Area/Main/Merge">002740</idno><idno type="wicri:Area/Main/Curation">002704</idno><idno type="wicri:Area/Main/Exploration">002704</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A conceptual framework for clinical trials in SLE and other multisystem diseases</title><author wicri:is="90%"><name sortKey="Liang, Matthew H" sort="Liang, Matthew H" uniqKey="Liang M" first="Matthew H" last="Liang">Matthew H. Liang</name></author><author wicri:is="90%"><name sortKey="Corzillius, Michael" sort="Corzillius, Michael" uniqKey="Corzillius M" first="Michael" last="Corzillius">Michael Corzillius</name></author><author wicri:is="90%"><name sortKey="Bae, Sang Cheol" sort="Bae, Sang Cheol" uniqKey="Bae S" first="Sang-Cheol" last="Bae">Sang-Cheol Bae</name><affiliation><wicri:noCountry code="subField">Center</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Fortin, Paul" sort="Fortin, Paul" uniqKey="Fortin P" first="Paul" last="Fortin">Paul Fortin</name><affiliation><wicri:noCountry code="subField">Hospital</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Esdaile, John M" sort="Esdaile, John M" uniqKey="Esdaile J" first="John M" last="Esdaile">John M. Esdaile</name><affiliation><wicri:noCountry code="subField">Columbia</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Abrahamowicz, Michal" sort="Abrahamowicz, Michal" uniqKey="Abrahamowicz M" first="Michal" last="Abrahamowicz">Michal Abrahamowicz</name><affiliation wicri:level="4"><country>Canada</country><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName><orgName type="university">Université McGill</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Lupus</title><idno type="ISSN">0961-2033</idno><idno type="eISSN">1477-0962</idno><imprint><publisher>Sage Publications</publisher><pubPlace>Sage CA: Thousand Oaks, CA</pubPlace><date type="published" when="1999-10">1999-10</date><biblScope unit="volume">8</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="570">570</biblScope><biblScope unit="page" to="580">580</biblScope></imprint><idno type="ISSN">0961-2033</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0961-2033</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active control equivalence studies</term><term>Active disease</term><term>Activity measure</term><term>Adequate power</term><term>Adverse effects</term><term>Alternative hypothesis</term><term>Arch neurol</term><term>Ares</term><term>Arthritis</term><term>Arthritis rheum</term><term>Arthritis society</term><term>Autoimmune diseases</term><term>Autoimmune disorders</term><term>Baillieres clin rheumatol</term><term>Chronic pain</term><term>Clin</term><term>Clin epidemiol</term><term>Clinical manifestations</term><term>Clinical trial</term><term>Clinical trials</term><term>Combination therapy</term><term>Conceptual framework</term><term>Congestive heart failure</term><term>Control clin trials</term><term>Cutaneous manifestations</term><term>Disease activity</term><term>Dos</term><term>Effectiveness trials</term><term>Eligibility criteria</term><term>Eligible patients</term><term>Endpoint</term><term>Entry criteria</term><term>Equivalence</term><term>Equivalence hypothesis</term><term>Equivalence trial</term><term>Equivalence trials</term><term>Erythematosus</term><term>Exclusion criteria</term><term>Experimental treatment</term><term>Fatigue severity scale</term><term>Generic measures</term><term>Health status</term><term>Homogeneous population</term><term>Impairment</term><term>Important difference</term><term>Individual patients</term><term>Induction trials</term><term>Liang</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus manifestations</term><term>Lupus nephritis</term><term>Maintenance trials</term><term>Major change</term><term>Manifestation</term><term>Meaningful change</term><term>More drugs</term><term>Multiple organ systems</term><term>Multiple sclerosis</term><term>Null hypothesis</term><term>Organ damage</term><term>Organ involvement</term><term>Organ system</term><term>Other diseases</term><term>Other hand</term><term>Outcome measures</term><term>Parallel approach</term><term>Partial remission</term><term>Physiologic health</term><term>Placebo</term><term>Primary endpoint</term><term>Proportional hazards model</term><term>Rand corporation</term><term>Randomized</term><term>Relapse</term><term>Remission</term><term>Renal disease</term><term>Respiratory hazards</term><term>Response criteria</term><term>Response criterion</term><term>Rheumatoid arthritis</term><term>Sample size</term><term>Sample size calculations</term><term>Sample size estimates</term><term>Sample size formulae</term><term>Santa monica</term><term>Severe disease</term><term>Simulation study</term><term>Single organ</term><term>Standard therapy</term><term>Standard treatment</term><term>Statist assoc</term><term>Statistical power</term><term>Steroid</term><term>Study agent</term><term>Study question</term><term>Such cases</term><term>Such changes</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Treatment effect</term><term>True difference</term><term>Vascular disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader></TEI><affiliations><list><country><li>Canada</li></country><region><li>Québec</li></region><settlement><li>Montréal</li></settlement><orgName><li>Université McGill</li></orgName></list><tree><noCountry><name sortKey="Bae, Sang Cheol" sort="Bae, Sang Cheol" uniqKey="Bae S" first="Sang-Cheol" last="Bae">Sang-Cheol Bae</name><name sortKey="Corzillius, Michael" sort="Corzillius, Michael" uniqKey="Corzillius M" first="Michael" last="Corzillius">Michael Corzillius</name><name sortKey="Esdaile, John M" sort="Esdaile, John M" uniqKey="Esdaile J" first="John M" last="Esdaile">John M. Esdaile</name><name sortKey="Fortin, Paul" sort="Fortin, Paul" uniqKey="Fortin P" first="Paul" last="Fortin">Paul Fortin</name><name sortKey="Liang, Matthew H" sort="Liang, Matthew H" uniqKey="Liang M" first="Matthew H" last="Liang">Matthew H. Liang</name></noCountry><country name="Canada"><region name="Québec"><name sortKey="Abrahamowicz, Michal" sort="Abrahamowicz, Michal" uniqKey="Abrahamowicz M" first="Michal" last="Abrahamowicz">Michal Abrahamowicz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002704 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002704 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7EDCF533E797A0FD0E6AA6FD1F6434EC7974C335
|texte= A conceptual framework for clinical trials in SLE and other multisystem diseases
}}
| This area was generated with Dilib version V0.6.33. |  |